In my portfolio, TWLO is my largest position at around 15%, not including the call leap options I also own. I’m not selling any ahead of earnings and will decide what to do next after I see the results.
Someone asked: I was thinking about buying more as I understand a little better what they do than it’s the case with most companies I own… Good time today or too risky?
No idea in the short term, as I don’t know their recent earnings yet and It depends on your current position and the percentage of your portfolio… and of course on your conviction in this particular company. I would refer you to my post above on buying in thirds. If you like the company and are still establishing a complete position, then it may make sense to pick up another 1/3 position and see how they do in their earnings release tomorrow. Personally, I am not buying any more before earnings, as I already have a full position and it’s my largest holding. And I am also not selling until I see how they do. I like the company, though, and believe they will do well long-term…and hopefully the stock price will eventually reflect the company success.
• Twilio (NYSE:TWLO) is scheduled to announce Q4 earnings results on Tuesday, February 12th, after market close.
• The consensus EPS Estimate is $0.04 (+233.3% Y/Y) and the consensus Revenue Estimate is $184.47M (+60.1% Y/Y).
• Over the last 2 years, TWLO has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time.
TWLO Is crushing it! I view any drop in the stock as a buying opportunity. (traders selling the news!). They continue to accelerate in revenue growth and customer growth. They just went from 60% growth to 77% growth one Quarter.I am looking forward to the earnings call tonight.
• Twilio (NYSE:TWLO) shares drop 2.8% on Q4 results that beat revenue estimates with 77% Y/Y growth but met on EPS.
• Q1 and FY19 guidance include the SendGrid acquisition (from February 1) and the consensus estimates don’t so the two aren’t comparable.
• Q1 guidance expects revenue from $222M to $225M with EPS from $0 to $0.01. FY19 guidance has revenue of $1.065B to $1.077B and EPS from $0.08 to $0.11.
• Q4 revenue breakdown: Base, $186.2M (consensus: $174.4M); Variable, $18.1M (consensus: $10.2M).
• Earnings call is scheduled for 5 PM ET with a webcast available
Someone asked: So Buy now?
I could not resist adding some TWLO this morning at $105. They just acquired another company called SendGrid who will be additive to their growth, but are not even included in the 77% revenue growth. $400m In 2017, $650m in 2018, and forecasting $1.1b in 2019. And they have beat their forecasts 9 out of the past 9 quarters they have been public. Pretty happy with these earnings myself and will sit tight with this investment for quite some time. Cheers!
Analysts playing catch up…duh!!
* Twilio Inc : Canaccord Genuity raises price target to $125 from $90
* Twilio Inc : Dougherty raises target price to $130 from $95
* Twilio Inc : Monnes, Crespi, Hardt and co raises target price to $150 from $117
* Twilio Inc : Oppenheimer raises target price to $125 from $110
That’s three $35 raises and a $15 raise.
Hope you got a nice discount on TWLO earlier today! ZS is my 6th largest holding at about 6.5% of my portfolio….and I have an additional synthetic long options position on the stock for 20 contracts….so yes, I am bullish. It’s only 3.7% below its all time high and earnings will come out next week on 2/21. It is highly valued, but if the earnings match previous quarters, that will adjust quickly.
Someone asked: And you’re out of NKTR right?
No. Not out. NKTR is my smallest position and my weakness. I did extremely well on CAR-T companies and feel this one is undervalued, but it’s definitely not in the same league as my top 10. I will hold it to see how the FDA clinical trials progress this year. I feel it could easily double or triple if any of its trials are fast tracked. Could be awhile and less than 1% of portfolio.
Yeah. No revenues. No earnings. No customers. No product. Just the hope of a better future for all of us who will eventually get cancer and a very cool new gene technology!!
Did anyone buy any ANET?! Wow! Crushes earnings release last night and up $20/share today. Up $60/share in the past 6 weeks. I no longer own this company, but nice to see them recovering and restarting their growth. What an awesome story!
